Here is the link
http://archneurosci.com/23640.pdf
Arch Neurosci. 2013 November; 1(2): 71-5. DOI: 10.5812/archneurosci.13687
Published online 2013 October 23. Research Article
Intrathecal Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A
Follow-Up Study for Five Years After Injection
Received: July 19, 2013; Revised: September 27, 2013; Accepted: September 28, 2013
Background: Mesenchymal stem cell therapy has been used in multiple sclerosis (MS) in order to modulate the course of the disease in
previous studies. One of the major concerns in such cases is long term safety or efficacy of this type of therapy.
Objectives: This study was conducted to report the clinical status of five patients with secondary progressive multiple sclerosis and one
patient with neuromyelitis optica, five years after an autologous intrathecal mesenchymal stem cell (MSC) injection.
Patients and Methods: The patients (three male, three female) had a progressive course nonresponsive to the conventional
immunomodulatory treatments with Expanded Disability Status Scale (EDSS) score of 3.5 to 6. They received the MCSs after discontinuing
other treatments. They were examined annually to assess the disease activity and possible complications.
Results: Two patients had no change in their EDSS scores. One was diagnosed to have Devic’s disease decreased one score in the EDSS,
but experienced four relapses during these five years. Three patients had an increase in EDSS scores by 1-2 scores after five years. Two
experienced relapses after injection. There was no significant adverse reaction, infection, or neoplasm during this period of follow up.
Conclusions: Intrathecal mesenchymal stem cell therapy for MS is generally safe and did not result in any adverse reaction like malignancy for a relatively long period of time. At least half of the patients had no change in their EDSS and the remaining patients had a delay in disease progress.
Keywords: Multiple Sclerosis; Stem Cells; Mesenchymal Stem Cell Transplantation; Tissue Therapy
During recent years a few studies have demonstrated safety and partial efficacy of mesenchymal stem cell transplantation in MS. As such studies are few
(less than 5), the long term safety is the major concern for all investigators. Our pilot safety study on this subject was published in 2007 and this manuscript
is the five-year follow-up of the original cases. The results of
our study can assist the investigators in determining the safety issues after stem cell transplantation in MS.
Copyright © 2013, Tehran University of Medical Sciences;
The full report is an interesting read
.
http://archneurosci.com/23640.pdf
Arch Neurosci. 2013 November; 1(2): 71-5. DOI: 10.5812/archneurosci.13687
Published online 2013 October 23. Research Article
Intrathecal Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A
Follow-Up Study for Five Years After Injection
Received: July 19, 2013; Revised: September 27, 2013; Accepted: September 28, 2013
Background: Mesenchymal stem cell therapy has been used in multiple sclerosis (MS) in order to modulate the course of the disease in
previous studies. One of the major concerns in such cases is long term safety or efficacy of this type of therapy.
Objectives: This study was conducted to report the clinical status of five patients with secondary progressive multiple sclerosis and one
patient with neuromyelitis optica, five years after an autologous intrathecal mesenchymal stem cell (MSC) injection.
Patients and Methods: The patients (three male, three female) had a progressive course nonresponsive to the conventional
immunomodulatory treatments with Expanded Disability Status Scale (EDSS) score of 3.5 to 6. They received the MCSs after discontinuing
other treatments. They were examined annually to assess the disease activity and possible complications.
Results: Two patients had no change in their EDSS scores. One was diagnosed to have Devic’s disease decreased one score in the EDSS,
but experienced four relapses during these five years. Three patients had an increase in EDSS scores by 1-2 scores after five years. Two
experienced relapses after injection. There was no significant adverse reaction, infection, or neoplasm during this period of follow up.
Conclusions: Intrathecal mesenchymal stem cell therapy for MS is generally safe and did not result in any adverse reaction like malignancy for a relatively long period of time. At least half of the patients had no change in their EDSS and the remaining patients had a delay in disease progress.
Keywords: Multiple Sclerosis; Stem Cells; Mesenchymal Stem Cell Transplantation; Tissue Therapy
During recent years a few studies have demonstrated safety and partial efficacy of mesenchymal stem cell transplantation in MS. As such studies are few
(less than 5), the long term safety is the major concern for all investigators. Our pilot safety study on this subject was published in 2007 and this manuscript
is the five-year follow-up of the original cases. The results of
our study can assist the investigators in determining the safety issues after stem cell transplantation in MS.
Copyright © 2013, Tehran University of Medical Sciences;
The full report is an interesting read
.
Comment